Literature DB >> 16443880

Serum lipids and the progression of nephropathy in type 1 diabetes.

Merlin C Thomas1, Milla Rosengård-Bärlund, Vashti Mills, Mats Rönnback, Stephen Thomas, Carol Forsblom, Mark E Cooper, Marja-Riitta Taskinen, Giancarlo Viberti, Per-Henrik Groop.   

Abstract

OBJECTIVE: Dyslipidemia contributes to the progression of microvascular disease in diabetes. However, different lipid variables may be important at different stages of nephropathy. This study examines the pattern of dyslipidemia associated with the progression of nephropathy in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: A total of 152 patients with type 1 diabetes were recruited in order to represent various phases of nephropathy. Patients were followed for 8-9 years, during which time they received standard care. Renal progression was defined a priori as a doubling in albumin excretion (in patients with normo- or microalbuminuria) or a decline in creatinine clearance (in those with macroalbuminuria). A panel of lipid variables was determined and correlated with indexes of progression.
RESULTS: In patients with normoalbuminuria (n = 66), progression was associated with male sex (P < 0.05), borderline albuminuria (P = 0.02), and LDL-free cholesterol (P = 0.02). In patients with microalbuminuria (n = 51), progression was independently associated with triglyceride content of VLDL and intermediate-density lipoprotein (both P < 0.05). In patients with macroalbuminuria (n = 36), a significant decline in the renal function (>3 ml x min(-1) x year(-1)) was independently associated with poor glycemic control, hypertension, and LDL size (P < 0.05). When all patients with progressive nephropathy were analyzed together, only LDL cholesterol was predictive on multivariate analysis (P < 0.05), which masked the importance of triglyceride enrichment in microalbuminuria.
CONCLUSIONS: Lipid variables are associated with progression of diabetic kidney disease, but the relationship is not the same at all stages. This finding has implications for the design of renoprotective strategies and the interpretation of clinical trials in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443880     DOI: 10.2337/diacare.29.02.06.dc05-0809

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  21 in total

1.  Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum.

Authors:  Ville-Petteri Mäkinen; Pasi Soininen; Carol Forsblom; Maija Parkkonen; Petri Ingman; Kimmo Kaski; Per-Henrik Groop; Mika Ala-Korpela
Journal:  MAGMA       Date:  2006-12-15       Impact factor: 2.310

2.  Oxidant/antioxidant status and hyperfiltration in young patients with type 1 diabetes mellitus.

Authors:  Roberto Hernández-Marco; Pilar Codoñer-Franch; Sara Pons Morales; Cristina Del Castillo Villaescusa; Laura Boix García; Victoria Valls Bellés
Journal:  Pediatr Nephrol       Date:  2008-09-10       Impact factor: 3.714

Review 3.  PPARalpha: an emerging therapeutic target in diabetic microvascular damage.

Authors:  Anne Hiukka; Marianna Maranghi; Niina Matikainen; Marja-Riitta Taskinen
Journal:  Nat Rev Endocrinol       Date:  2010-06-22       Impact factor: 43.330

4.  Hypertension is the metabolic syndrome component most strongly associated with microvascular complications and coronary artery calcification in Type 1 diabetes.

Authors:  T C Rodrigues; L H Canani; P Schvartzman; J L Gross
Journal:  J Endocrinol Invest       Date:  2010-09-17       Impact factor: 4.256

Review 5.  [Protection of renal function in diabetics].

Authors:  C Hasslacher
Journal:  Internist (Berl)       Date:  2007-07       Impact factor: 0.743

6.  Relationship between lipid profiles and kidney function in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; O Heikkilä; K Pettersson-Fernholm; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

7.  Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Authors:  E Ritz; G C Viberti; L M Ruilope; A J Rabelink; J L Izzo; S Katayama; S Ito; A Mimran; J Menne; L C Rump; A Januszewicz; H Haller
Journal:  Diabetologia       Date:  2009-10-30       Impact factor: 10.122

8.  Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients.

Authors:  T Bulum; B Kolaric; L Duvnjak
Journal:  J Endocrinol Invest       Date:  2013-02-12       Impact factor: 4.256

9.  Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; M Feodoroff; V-P Mäkinen; D Gordin; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2009-10-10       Impact factor: 10.122

Review 10.  Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.

Authors:  Merlin C Thomas; Mark E Cooper; Paul Zimmet
Journal:  Nat Rev Nephrol       Date:  2015-11-10       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.